Search
INmune Bio Inc
INMBAdd to Watchlist
1.700USD
+0.020+1.19%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
45.19MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.19%
5 Days
+19.72%
1 Month
+25.93%
6 Months
+10.39%
Year to Date
+8.97%
1 Year
-32.81%
Key Figures
1.720Open
1.740High
964.46KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.63%Turnover Ratio
1.680Prev. Close
1.625Low
1.22MTurnover
LossP/E Static
2.30P/B
0.00%Div Yield TTM
-130.78%ROA
11.64052wk High
1.16Volume Ratio
-42.08MNet Profit
26.59MShares
-1.6258EPS TTM
1.04Beta
-168.78%ROE
1.09052wk Low
6.85%Amplitude
100.00%Gross Margin
45.19MMarket Cap
5.46Reward/Risk
4.48%Risk Rate
TradingKey Stock Score of INmune Bio Inc
Currency: USD Updated: 2026-07-02Key Insights
INmune Bio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 122 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
INmune Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
INmune Bio Inc Highlights
StrengthsRisks
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Growing
The company is in a growing phase, with the latest annual income totaling USD 50.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 50.00K.
Fairly Valued
The company’s latest PE is -1.05, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.01M shares, decreasing 33.67% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 13.72K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
7.000
Target Price
+316.67%
Upside Space
INmune Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
INmune Bio Inc Info
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Ticker SymbolINMB
CompanyINmune Bio Inc
CEOMoss (David J)
Websitehttps://www.inmunebio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of INmune Bio Inc (INMB)?
The current price of INmune Bio Inc (INMB) is 1.70.
What is the symbol of INmune Bio Inc?
The ticker symbol of INmune Bio Inc is INMB.
What is the 52-week high of INmune Bio Inc?
The 52-week high of INmune Bio Inc is 11.64.
What is the 52-week low of INmune Bio Inc?
The 52-week low of INmune Bio Inc is 1.09.
What is the market capitalization of INmune Bio Inc?
The market capitalization of INmune Bio Inc is 45.19M.
Is INmune Bio Inc (INMB) currently rated as Buy, Hold, or Sell?
According to analysts, INmune Bio Inc (INMB) has an overall rating of Buy, with a price target of 7.00.
What is the Earnings Per Share (EPS TTM) of INmune Bio Inc (INMB)?
The Earnings Per Share (EPS TTM) of INmune Bio Inc (INMB) is -1.86.